文献速递免疫规划

第三剂BNT162b2疫苗在未感染SARS-CoV-2的新西兰队列中对Omicron变异株的稳健免疫原性

Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort.
PubMed 文献 · Vaccine · 2023-07-27

本研究在298名未感染SARS-CoV-2的新西兰成人中评估第三剂BNT162b2疫苗的免疫原性。结果显示第三剂显著提高所有亚组抗S-IgG滴度至少1.5倍,并诱导针对Omicron BA.1的中和反应(两剂后缺失)。

要点

  • 第三剂BNT162b2使所有人口学亚组抗S-IgG平均滴度较两剂后至少提高1.5倍。
  • 糖尿病参与者第三剂后抗体滴度升高约4倍,非糖尿病者约2倍。
  • 第三剂诱导针对Omicron BA.1的中和反应,两剂后未检测到。

核心结论

  • 在无既往SARS-CoV-2感染的新西兰成人队列中,第三剂BNT162b2疫苗增强免疫原性,包括针对Omicron BA.1的中和反应。

研究设计与样本

  • 成人队列研究,纳入298名参与者,过度抽样高风险人群,其中毛利人占29%、太平洋岛民占28%、55岁以上占40%。
  • 采集第二剂后28天和6个月、第三剂后28天的血清,检测SARS-CoV-2抗S-IgG滴度及针对包括Omicron BA.1在内的关注变异株的替代病毒中和试验中和能力。

主要发现

  • 第三剂前队列内SARS-CoV-2感染发生率很低(<6%)。
  • 第三剂疫苗使每个人口学亚组的平均SARS-CoV-2抗S-IgG滴度较两剂后至少提高1.5倍。
  • 糖尿病参与者第三剂后抗体滴度升高约4倍,非糖尿病者升高约2倍。
  • 第三剂诱导针对Omicron BA.1的中和反应,两剂后不存在;该中和反应改善与年龄、BMI、种族或糖尿病状态无关。
  • ≥75岁参与者在各时间点抗S-IgG滴度始终最低,但第三剂后改善幅度最大。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The ability of a third dose of the Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine to stimulate immune responses against subvariants, including Omicron BA.1, has not been assessed in New Zealand populations. Unlike many overseas populations, New Zealanders were largely infection naïve at the time they were boosted. This adult cohort of 298 participants, oversampled for at-risk populations, was composed of 29% Māori and 28% Pacific peoples, with 40% of the population aged 55+. A significant proportion of the cohort was obese and presented with at least one comorbidity. Sera were collected 28 days and 6 months post second vaccination and 28 days post third vaccination. SARS-CoV-2 anti-S IgG titres and neutralising capacity using surrogate viral neutralisation assays against variants of concern, including Omicron BA.1, were investigated. The incidence of SARS-CoV-2 infection, within our cohort, prior to third vaccination was very low (<6%). This study found a third vaccine significantly increased the mean SARS-CoV-2 anti-S IgG titres, for every demographic subgroup, by a minimum of 1.5-fold compared to titres after two doses. Diabetic participants experienced a greater increase (∼4-fold) in antibody titres after their third vaccination, compared to non-diabetics (increase of ∼ 2-fold). This corrected for the deficiency in antibody titres within diabetic participants which was observed following two doses. A third dose also induced a neutralising response against Omicron variant BA.1, which was absent after two doses. This neutralising response improved regardless of age, BMI, ethnicity, or diabetes status. Participants aged ≥75 years consistently had the lowest SARS-CoV-2 anti-S IgG titres at each timepoint, however experienced the greatest improvement after three doses compared to younger participants. This study shows that in the absence of prior SARS-CoV-2 infection, a third Pfizer-BioNTech BNT162b2 vaccine enhances immunogenicity, including against Omicron BA.1, in a cohort representative of at-risk groups in the adult New Zealand population.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lavender B, Hooker C, Frampton C, et al. Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort. Vaccine. 2023. PMID: 37516574. doi:10.1016/j.vaccine.2023.07.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。